DE69635213D1 - Verwendung von Olanzapin zur Behandlung von mentalen Erkrankungen verursacht durch zerebrovaskuläre Erkrankungen - Google Patents
Verwendung von Olanzapin zur Behandlung von mentalen Erkrankungen verursacht durch zerebrovaskuläre ErkrankungenInfo
- Publication number
- DE69635213D1 DE69635213D1 DE69635213T DE69635213T DE69635213D1 DE 69635213 D1 DE69635213 D1 DE 69635213D1 DE 69635213 T DE69635213 T DE 69635213T DE 69635213 T DE69635213 T DE 69635213T DE 69635213 D1 DE69635213 D1 DE 69635213D1
- Authority
- DE
- Germany
- Prior art keywords
- olanzapine
- treatment
- cerebrovascular diseases
- mental illnesses
- illnesses caused
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 208000026106 cerebrovascular disease Diseases 0.000 title abstract 2
- KVWDHTXUZHCGIO-UHFFFAOYSA-N olanzapine Chemical compound C1CN(C)CCN1C1=NC2=CC=CC=C2NC2=C1C=C(C)S2 KVWDHTXUZHCGIO-UHFFFAOYSA-N 0.000 title abstract 2
- 229960005017 olanzapine Drugs 0.000 title abstract 2
- 208000020016 psychiatric disease Diseases 0.000 title abstract 2
- 239000003795 chemical substances by application Substances 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 229940124597 therapeutic agent Drugs 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/26—Psychostimulants, e.g. nicotine, cocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Psychiatry (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Anesthesiology (AREA)
- Urology & Nephrology (AREA)
- Hospice & Palliative Care (AREA)
- Pain & Pain Management (AREA)
- Vascular Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Other In-Based Heterocyclic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP00319195A JP3274579B2 (ja) | 1995-01-12 | 1995-01-12 | 脳血管障害に伴う精神症候治療剤 |
JP319195 | 1995-01-12 |
Publications (2)
Publication Number | Publication Date |
---|---|
DE69635213D1 true DE69635213D1 (de) | 2006-02-02 |
DE69635213T2 DE69635213T2 (de) | 2006-11-23 |
Family
ID=11550523
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DE69618047T Expired - Lifetime DE69618047T2 (de) | 1995-01-12 | 1996-01-11 | Verwendung von Serotonin- und Dopaminrezeptorblockern zur Behandlung von mentalen Erkrankungen verursacht durch zerebrovaskuläre Erkrankungen |
DE69635213T Expired - Lifetime DE69635213T2 (de) | 1995-01-12 | 1996-01-11 | Verwendung von Olanzapin zur Behandlung von mentalen Erkrankungen,verursacht durch cerebrovaskuläre Erkrankungen |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DE69618047T Expired - Lifetime DE69618047T2 (de) | 1995-01-12 | 1996-01-11 | Verwendung von Serotonin- und Dopaminrezeptorblockern zur Behandlung von mentalen Erkrankungen verursacht durch zerebrovaskuläre Erkrankungen |
Country Status (10)
Country | Link |
---|---|
EP (2) | EP0730865B1 (de) |
JP (1) | JP3274579B2 (de) |
KR (1) | KR100397525B1 (de) |
CN (1) | CN1088359C (de) |
AT (2) | ATE304855T1 (de) |
CA (1) | CA2167004C (de) |
DE (2) | DE69618047T2 (de) |
DK (1) | DK0730865T3 (de) |
ES (2) | ES2249352T3 (de) |
PT (1) | PT730865E (de) |
Families Citing this family (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
UA57727C2 (uk) * | 1996-03-11 | 2003-07-15 | Елі Ліллі Енд Компані | Спосіб лікування надмірної агресивності |
WO1997035584A1 (en) * | 1996-03-25 | 1997-10-02 | Eli Lilly And Company | Method for treating pain |
EP1155696B1 (de) * | 1997-04-15 | 2004-03-03 | Eli Lilly And Company | Verwendung von Olanzapin zur Herstellung eines Arzneimittels zur Neuroprotektion |
US5902807A (en) * | 1997-05-12 | 1999-05-11 | Antti Haapalinna | Method for the treatment of mental illness in mammals and a composition therefor |
WO1999032108A1 (en) * | 1997-12-19 | 1999-07-01 | Akzo Nobel N.V. | Org-5222 in the treatment of depression |
UA70334C2 (en) * | 1998-10-06 | 2004-10-15 | Janssen Pharmaceutica N V Jans | BENZOTHIENO[3,2-c]PYRIDINES AS a2 ANTAGONISTS BENZOTHIENO[3,2-c]PYRIDINES AS a2 ANTAGONISTS |
JP2004262812A (ja) * | 2003-02-28 | 2004-09-24 | Rohto Pharmaceut Co Ltd | 眼圧低下剤 |
WO2004100954A1 (en) * | 2003-05-16 | 2004-11-25 | Pfizer Products Inc. | Treatment of psychotic and depressive disorders |
US8852638B2 (en) | 2005-09-30 | 2014-10-07 | Durect Corporation | Sustained release small molecule drug formulation |
EP2036559B1 (de) * | 2006-06-09 | 2014-03-19 | Dainippon Sumitomo Pharma Co., Ltd. | Pflasterzubereitung |
CN101801415B (zh) | 2007-05-25 | 2015-09-23 | Rb医药品有限公司 | 利培酮化合物的持续递送制剂 |
RU2762896C2 (ru) | 2016-12-20 | 2021-12-23 | Лтс Ломанн Терапи-Систем Аг | Трансдермальная терапевтическая система, содержащая азенапин |
RU2764443C2 (ru) | 2016-12-20 | 2022-01-17 | Лтс Ломанн Терапи-Систем Аг | Трансдермальная терапевтическая система, содержащая азенапин и полисилоксан или полиизобутилен |
WO2019002204A1 (en) | 2017-06-26 | 2019-01-03 | Lts Lohmann Therapie-Systeme Ag | TRANSDERMAL THERAPEUTIC SYSTEM CONTAINING ASENAPINE AND SILICONE-TYPE ACRYLIC HYBRID POLYMER |
CN112704672A (zh) | 2018-06-20 | 2021-04-27 | 罗曼治疗系统股份公司 | 含有阿塞那平的透皮治疗系统 |
CA3126331A1 (en) * | 2019-01-09 | 2020-07-16 | Ken-ichi YAMADA | Pharmaceutical composition for treatment of dementia and cerebrovascular disorders |
Family Cites Families (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
NL7605526A (nl) * | 1976-05-24 | 1977-11-28 | Akzo Nv | Nieuwe tetracyclische derivaten. |
NO154582C (no) * | 1978-10-20 | 1986-11-05 | Ferrosan Ab | Analogifremgangsmaate for fremstilling av terapeutisk aktive difenyl-dibutylpiperazinkarboksamider. |
JPH0625181B2 (ja) * | 1985-03-27 | 1994-04-06 | 住友製薬株式会社 | 新規なイミド誘導体 |
US4804663A (en) * | 1985-03-27 | 1989-02-14 | Janssen Pharmaceutica N.V. | 3-piperidinyl-substituted 1,2-benzisoxazoles and 1,2-benzisothiazoles |
IE58370B1 (en) * | 1985-04-10 | 1993-09-08 | Lundbeck & Co As H | Indole derivatives |
US4636563A (en) * | 1985-09-16 | 1987-01-13 | American Home Products Corporation | Antipsychotic γ-carbolines |
MX173362B (es) * | 1987-03-02 | 1994-02-23 | Pfizer | Compuestos de piperazinil heterociclicos y procedimiento para su preparacion |
JPH0747574B2 (ja) * | 1989-03-03 | 1995-05-24 | 大日本製薬株式会社 | ピリジン誘導体及びそれを有効成分とする向精神剤 |
ATE126512T1 (de) * | 1989-05-19 | 1995-09-15 | Hoechst Roussel Pharma | N-(aryloxyalkyl)heteroarylpiperidine und - heteroarylpiperazine, verfahren zu ihrer herstellung und ihre verwendung als medikamente. |
NZ236501A (en) * | 1989-12-21 | 1992-12-23 | Merrell Dow Pharma | Piperidine derivatives and antithrombotic compositions |
GB9008850D0 (en) * | 1990-04-19 | 1990-06-13 | Janssen Pharmaceutica Nv | Novel 2,9-disubstituted-4h-pyridol(1,2-a)pyrimidin-4-ones |
GB9009229D0 (en) * | 1990-04-25 | 1990-06-20 | Lilly Industries Ltd | Pharmaceutical compounds |
JP3063263B2 (ja) * | 1991-07-31 | 2000-07-12 | スズキ株式会社 | ミッションケース構造 |
TW385302B (en) * | 1992-11-30 | 2000-03-21 | Sankyo Co | Alpha, omega-diarylalkane derivatives, their preparation and their use in the treatment and prevention of circulatory diseases and psychosis |
GB9302622D0 (en) * | 1993-02-10 | 1993-03-24 | Wellcome Found | Heteroaromatic compounds |
JP3007257B2 (ja) * | 1994-03-03 | 2000-02-07 | ローム株式会社 | サーマルプリントヘッド |
CA2144669A1 (en) * | 1994-03-29 | 1995-09-30 | Kozo Akasaka | Biphenyl derivatives |
CZ292565B6 (cs) * | 1995-05-30 | 2003-10-15 | Eli Lilly And Company | Použití 2-methyl-4-(4-methyl-1-piperazinyl)-10H-thieno[2,3-b][1,5]benzodiazepinu k přípravě farmaceutického prostředku pro léčení kognitivní dysfunkce |
-
1995
- 1995-01-12 JP JP00319195A patent/JP3274579B2/ja not_active Expired - Fee Related
-
1996
- 1996-01-11 AT AT01112981T patent/ATE304855T1/de not_active IP Right Cessation
- 1996-01-11 PT PT96100360T patent/PT730865E/pt unknown
- 1996-01-11 ES ES01112981T patent/ES2249352T3/es not_active Expired - Lifetime
- 1996-01-11 EP EP96100360A patent/EP0730865B1/de not_active Expired - Lifetime
- 1996-01-11 DE DE69618047T patent/DE69618047T2/de not_active Expired - Lifetime
- 1996-01-11 KR KR1019960000461A patent/KR100397525B1/ko not_active IP Right Cessation
- 1996-01-11 AT AT96100360T patent/ATE210984T1/de active
- 1996-01-11 DE DE69635213T patent/DE69635213T2/de not_active Expired - Lifetime
- 1996-01-11 CA CA002167004A patent/CA2167004C/en not_active Expired - Fee Related
- 1996-01-11 ES ES96100360T patent/ES2170176T3/es not_active Expired - Lifetime
- 1996-01-11 EP EP01112981A patent/EP1181935B1/de not_active Expired - Lifetime
- 1996-01-11 DK DK96100360T patent/DK0730865T3/da active
- 1996-01-12 CN CN96101615A patent/CN1088359C/zh not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
CA2167004C (en) | 2006-09-12 |
DE69618047D1 (de) | 2002-01-31 |
EP0730865A1 (de) | 1996-09-11 |
CN1142945A (zh) | 1997-02-19 |
CA2167004A1 (en) | 1996-07-13 |
DE69635213T2 (de) | 2006-11-23 |
CN1088359C (zh) | 2002-07-31 |
ATE210984T1 (de) | 2002-01-15 |
KR100397525B1 (ko) | 2003-11-20 |
ES2249352T3 (es) | 2006-04-01 |
EP1181935A2 (de) | 2002-02-27 |
DE69618047T2 (de) | 2002-06-20 |
EP0730865B1 (de) | 2001-12-19 |
DK0730865T3 (da) | 2002-04-02 |
EP1181935A3 (de) | 2002-03-06 |
PT730865E (pt) | 2002-04-29 |
EP1181935B1 (de) | 2005-09-21 |
JP3274579B2 (ja) | 2002-04-15 |
JPH08193033A (ja) | 1996-07-30 |
ATE304855T1 (de) | 2005-10-15 |
ES2170176T3 (es) | 2002-08-01 |
KR960028905A (ko) | 1996-08-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DE69635213D1 (de) | Verwendung von Olanzapin zur Behandlung von mentalen Erkrankungen verursacht durch zerebrovaskuläre Erkrankungen | |
DE60027732D1 (de) | Verwendung von anti-rubeola antkörpern zur behandlung von symptomen von erkrankungen des zentralen nervensystems | |
NO20035474D0 (no) | Prodrugs av GABA-analoger, sammensetninger og anvendelse derav | |
UA27911C2 (uk) | Засіб для лікування або запобігання фізіологічних розладів, які викликані надлишком тахікініну | |
DE19680619D2 (de) | Verwendung von Adamantan-Derivaten zur Behandlung von Erkrankungen des Innenohrs | |
DE69616376T2 (de) | Verwendung von Tiagabin zur Behandlung von Schlafstörungen | |
DE69626539D1 (de) | topische Verwendung von Vitamin D zur Behandlung von Augenerkrankungen | |
DE69534908D1 (de) | Verwendung von statin zur behandlung von hauterkrankungen | |
ATE125704T1 (de) | Behandlung neurodegenerativer erkrankungen. | |
DE69431199D1 (de) | Melatonin-Derivate zur Verwendung in der Behandlung von Schlafstörungen | |
ATE239470T1 (de) | Melatonin-derivate zur verwendung in der behandlung von desynchronisierungs-erkankungen | |
ATE431735T1 (de) | Fusionierte cycloalkyl amid- und carbonsäure- derivate und deren therapeutische verwendung zur behandlung von u.a. epilepsie | |
DE9305147U1 (de) | Trainingsgerät zur Behandlung von an Wahrnehmungsstörungen leidenden Patienten | |
DE69729735D1 (de) | Verwendung von benzopyranolen zur behandlung von neurologischen erkrankungen | |
ATE290866T1 (de) | Verwendung von stimulatoren der neurotrophischen faktoren zur behandlung von neurodegenerativen ophthalmischen krankheiten | |
DE69736180D1 (de) | Behandlung von manischen erkrankungen | |
DE69623767D1 (de) | Verwendung von pyrrolidinderivaten zur behandlung des alkoholismus | |
DE59609219D1 (de) | Verwendung von 1-hydroxy-2-pyridonen zur behandlung von schwer therapierbaren schleimhauterkrankungen | |
DE69807586D1 (de) | Verwendung eines Alkylendioxybenzolderivats zur Behandlung von zirkadianen Schlafstörungen | |
ATE299021T1 (de) | Verwendung von oxazolidinonderivaten zur behandlung von psoriasis | |
DE69915849D1 (de) | Verwendung von gnrh analogen zur behandlung von schizophrenie | |
ATE232736T1 (de) | Zusammensetzungen zur vorbeugung und behandlung von urogenitalen störungen, die wismut enthalten | |
ATE247467T1 (de) | Neue therapeutische verwendung von 1,6-dimethyl- 8beta-hydroxymethyl-10alpha-methoxyergolin |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
8327 | Change in the person/name/address of the patent owner |
Owner name: DAINIPPON SUMITOMO PHARMA CO., LTD., OSAKA, JP |
|
8332 | No legal effect for de | ||
8370 | Indication related to discontinuation of the patent is to be deleted | ||
8364 | No opposition during term of opposition |